Welcome to our dedicated page for ARROWHEAD PHARMACEUTICALS SEC filings (Ticker: ARWR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ARROWHEAD PHARMACEUTICALS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ARROWHEAD PHARMACEUTICALS's regulatory disclosures and financial reporting.
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) director Adeoye Y. Olukotun reported a sale of 2,000 shares of common stock on 2026-08-18 in an open-market or private transaction at $86.96 per share. Following this transaction, he directly holds 31,600 shares, which the company notes include previously reported shares underlying Restricted Stock Units, some of which remain subject to vesting conditions.
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) director Michael S. Perry reported a sale of 11,600 shares of common stock on 2026-08-18. The price reported is a weighted average of $87.30 per share, with individual trades between $87.20 and $87.44. Following this transaction, he directly holds 111,459 shares, which include previously reported shares underlying Restricted Stock Units, some of which remain subject to vesting conditions. The filing indicates the Rule 10b5-1 trading plan checkbox was not marked.
Arrowhead Pharmaceuticals Inc. (ARWR) received a Rule 144 notice from director Adeoye Olukotun regarding a proposed sale of common stock. The filing states an intention to sell 2,000 shares of Arrowhead common stock through Merrill Lynch, with an aggregate market value of $173,876.47, on or about 08/18/2026 on NASDAQ. The company reports 141,254,467 shares outstanding. The 2,000 shares to be sold were acquired from the issuer as compensation on 12/18/2025.
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) director Michael Perry has filed a notice of proposed sale of common stock under Rule 144. He plans to sell up to 11,600 shares of Arrowhead common stock through Merrill Lynch on NASDAQ, with an estimated aggregate market value of $1,012,171.97. The shares were acquired from the issuer as compensation on several dates in 2021, 2022, and 2025. Arrowhead had 141,254,467 shares outstanding of common stock; this is a baseline figure, not the amount being offered.
Arrowhead Pharmaceuticals, Inc. reported that investment firm Avoro Capital Advisors LLC and its controlling person Behzad Aghazadeh beneficially own 13,823,383 shares of Common Stock, including 2,467,828 shares issuable upon exercise of warrants. Based on 140,857,021 shares of Common Stock outstanding as of May 1, 2026, this represents 9.64% of Arrowhead’s outstanding Common Stock, assuming the warrants are exercised.
The reporting persons state they hold sole voting and sole dispositive power over all 13,823,383 shares, with no shared voting or dispositive power. The position is held for investment purposes on behalf of Avoro Life Sciences Fund LLC, and the filers note that this report does not constitute an admission of beneficial ownership for legal purposes.
Arrowhead Pharmaceuticals reported fiscal 2026 third quarter results for the period ended June 30, 2026. Revenue was $75,253 thousand, up from $27,767 thousand a year earlier, while total operating expenses rose to $245,346 thousand, leading to a net loss attributable to Arrowhead of $194,280 thousand, or $(1.36) per diluted share.
Total cash resources, including cash and available-for-sale securities, were $1,566,886 thousand at June 30, 2026, against total liabilities of $1,645,972 thousand, including $682,707 thousand of convertible notes. REDEMPLO® commercial momentum continued, with prescription volume roughly doubling and new marketing authorizations in the EU and Australia.
Topline Phase 3 SHASTA-3 and SHASTA-4 data for plozasiran in severe hypertriglyceridemia showed median triglyceride reductions of 79% and 81%, and a 78% reduction in acute pancreatitis events, including 100% reduction in a highest‑risk subgroup. Arrowhead acquired an FDA priority review voucher and signed a global license for ARO‑PNPLA3 with Madrigal, receiving a $25 million upfront payment and eligibility for up to $975 million in milestones.
Vanguard Portfolio Management LLC, together with certain affiliates, reports beneficial ownership of Arrowhead Pharmaceuticals Inc. common stock. The group holds 6,384,903 shares, representing 4.53% of the outstanding class of Arrowhead’s common stock.
Within this position, Vanguard Portfolio Management has sole voting power over 33,548 shares and sole dispositive power over 6,384,903 shares, with no shared voting or dispositive power reported. The stake is held across Vanguard investment companies and other managed accounts for which Vanguard entities exercise voting and/or dispositive authority. No other individual investor’s interest in the reported securities exceeds 5% of the class.
BlackRock, Inc. filed an amended Schedule 13G reporting a significant ownership position in Arrowhead Pharmaceuticals Inc. common stock. BlackRock reports beneficial ownership of 14,232,545 shares, representing 10.1% of Arrowhead’s outstanding common stock.
BlackRock has sole voting power over 13,849,022 shares and sole dispositive power over 14,232,545 shares, with no shared voting or dispositive power. Various underlying clients have economic rights to dividends and sale proceeds, but no individual client holds more than five percent of Arrowhead’s outstanding common shares.
Arrowhead Pharmaceuticals director Matthew Gregory Cohen received an equity award. On the grant dated 06/15/2026, he acquired 11,882 shares of Common Stock underlying restricted stock units at no cash cost. These units vest over three years, and following the grant he directly holds 11,882 shares.